A phase I/II study of pemetrexed with sirolimus in advanced,
previously treated non-small cell lung cancer by Komiya, Takefumi et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Public Health Resources Public Health Resources 
2019 
A phase I/II study of pemetrexed with sirolimus in advanced, 
previously treated non-small cell lung cancer 
Takefumi Komiya 
Regan M. Memmott 
Gideon M. Blumenthal 
Wendy Bernstein 
Marc S. Ballas 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/publichealthresources 
This Article is brought to you for free and open access by the Public Health Resources at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources 
by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
Takefumi Komiya, Regan M. Memmott, Gideon M. Blumenthal, Wendy Bernstein, Marc S. Ballas, Roopa De 
Chowdhurry, Guinevere Chun, Cody J. Peer, William D. Figg, David J. Liewehr, Seth M. Steinberg, Giuseppe 
Giaccone, Eva Szabo, Shigeru Kawabata, Junji Tsurutani, Arun Rajan, and Phillip A. Dennis 
© Translational lung cancer research. All rights reserved.   Transl Lung Cancer Res 2019;8(3):247-257 | http://dx.doi.org/10.21037/tlcr.2019.04.19
Original Article
A phase I/II study of pemetrexed with sirolimus in advanced, 
previously treated non-small cell lung cancer
Takefumi Komiya1,a, Regan M. Memmott1, Gideon M. Blumenthal1, Wendy Bernstein1, Marc S. Ballas1, 
Roopa De Chowdhury1, Guinevere Chun1, Cody J. Peer1, William D. Figg1, David J. Liewehr2, 
Seth M. Steinberg2, Giuseppe Giaccone1,b, Eva Szabo1,3, Shigeru Kawabata1, Junji Tsurutani1, 
Arun Rajan1, Phillip A. Dennis1,c
1Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; 2Biostatistics and Data Management 
Section, National Cancer Institute, Rockville, MD, USA; 3Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, 
National Cancer Institute, Bethesda, MD, USA
Contributions: (I) Conception and design: GM Blumenthal, MS Ballas, PA Dennis; (II) Administrative support: G Chun; (III) Provision of study 
materials or patients: All authors; (IV) Collection and assembly of data: T Komiya, RM Memmott, CJ Peer, WD Figg, DJ Liewehr, SM Steinberg; (V) 
Data analysis and interpretation: T Komiya, RM Memmott, CJ Peer, WD Figg, DJ Liewehr, SM Steinberg; (VI) Manuscript writing: All authors; (VII) 
Final approval of manuscript: All authors.
Correspondence to: Takefumi Komiya, MD, PhD. Hematology/Medical Oncology, Parkview Cancer Institute, 11050 Parkview Circle, Fort Wayne, IN 
46845, USA. Email: takefumi.komiya@parkview.com.
Background: Single-agent pemetrexed is a treatment for recurrent non-squamous non-small cell lung 
cancer (NSCLC) that provides limited benefit. Preclinical studies showed promising synergistic effects when 
the mammalian target of rapamycin (mTOR) inhibitor sirolimus was added to pemetrexed.
Methods: This was a single-institution phase I/II study of pemetrexed in combination with sirolimus. The 
primary endpoint for the phase I was to determine the maximum tolerated dose (MTD) and safety of the 
combination. The primary endpoint for the phase II portion was to determine the overall response rate at 
the MTD. Key eligibility criteria included recurrent, metastatic NSCLC, ECOG performance status of 
0–2, and adequate organ function. Sirolimus was administered orally daily after an initial loading dose, and 
pemetrexed was given intravenously on day 1 of every 21-day cycle. 
Results: Forty-two patients with recurrent, metastatic NSCLC were enrolled, 22 in phase I and 20 
in phase II. The MTD was pemetrexed 500 mg/m2 every 3 weeks, and sirolimus 10 mg on day 1, and  
3 mg daily thereafter. Treatment-related adverse events (AEs) occurred in 38 (90.5%) patients. The most 
common grade 3–4 treatment-related AEs were lymphopenia (31%) and hypophosphatemia (19%). Two 
treatment-related deaths occurred due to febrile neutropenia and infection, respectively. Among 27 total 
patients treated at the MTD, 6 (22.2%) had a partial response (PR), 12 (44.4%) had stable disease (SD) and  
5 (18.5%) had progressive disease. Median progression-free survival (PFS) was 18.4 weeks (95% CI: 7.0–29.4). 
Conclusions: The combination of pemetrexed and sirolimus is active in heavily-pretreated NSCLC 
(ClinicalTrials.gov Identifier: NCT00923273).
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Introduction
Non-small cell lung cancer (NSCLC) accounts for the 
highest cancer mortality in the US, killing more than 
150,000 people annually (1). Approximately 30–40% of 
NSCLC patients present with metastatic disease where 
only systemic therapy has an impact on survival (2). 
Once patients relapse after initial treatment, they have 
limited therapeutic options that can modestly improve 
survival. At the time this study was conducted, approved 
chemotherapies in this setting included single-agent 
pemetrexed and docetaxel (3,4). 
Discovery of driver oncogenes such as epidermal growth 
factor receptor (EGFR) led to development of tyrosine 
kinase inhibitors, benefiting patients with activating 
mutations or translocations. However, the population 
with driver mutations for which tyrosine kinase inhibitors 
are available is small in Western countries (20% in 
Caucasians), limiting its application to a subset of patients, 
and development of resistance is an inevitable consequence 
of treatment (5). More recently, a greater understanding 
of tumor immunology has resulted in the identification of 
immune checkpoints that can be therapeutically targeted to 
enhance anti-tumor immune responses. Antibodies targeting 
the programed death-1 (PD-1) and its ligand (PD-L1) (e.g., 
nivolumab, pembrolizumab, and atezolizumab), have been 
approved for treatment of metastatic NSCLC (6). Although 
durable benefit is observed in patients responding to 
treatment, a relatively small number of patients develop an 
objective response to immune checkpoint inhibition therapy 
and escape mechanisms ultimately result in development of 
resistance in most cases. Despite the promise and benefit 
of targeted therapies and immunotherapies in selected 
NSCLC populations, newer forms of treatment are needed 
to expand the efficacy of standard agents such as pemetrexed 
in patients with advanced NSCLC.
Our group has previously demonstrated that the Akt-
mammalian target of rapamycin (mTOR) pathway is 
frequently activated in NSCLC, and its activation is 
associated with a worse clinical outcome (7,8). Several 
agents related to rapamycin targeting mTOR signaling 
are clinically available. Temsirolimus (Torisel®) and 
everolimus (Afinitor®) are approved in the first and second-
line treatment of renal cell carcinoma, respectively (9,10). 
Sirolimus (Rapamune®) is indicated for post-transplant 
immunosuppression, with a well described toxicity 
profile (11). Preclinical studies from our group showed 
a synergistic anti-cancer effect between pemetrexed and 
sirolimus in vitro and in vivo. Sirolimus blocks pemetrexed-
induced thymidylate synthase (TS) activation in vivo, 
which may further enhance activity of pemetrexed (12). 
The addition of mTOR inhibitors such as sirolimus may 
therefore synergistically cause anti-tumor effects. 
The combination of mTOR inhibitors with pemetrexed 
has previously been evaluated in small phase I trials and 
found to be safe and tolerable (13,14). To our knowledge 
this is the largest trial for the phase II portion reported 
to date to determine the safety and clinical activity of 
pemetrexed in combination with an mTOR inhibitor in 
previously treated NSCLC (13,14).
Methods
Study design and treatment
The study was approved by the National Cancer Institute 
(NCI) Institutional Review Board (IRB), conducted at the 
NCI, and registered in a clinical trial registry (ClinicalTrials.
gov Identifier: NCT00923273). All patients signed the 
written informed consent approved by the NCI IRB. 
The primary objective of the phase I portion of the study 
was to determine the maximum tolerated dose (MTD) of 
pemetrexed and sirolimus in combination in patients with 
NSCLC. The secondary objectives were to analyze the 
pharmacokinetics (PK) of both agents, and mTOR pathway 
inhibition in peripheral blood mononuclear cells (PBMC). 
A standard 3+3 dose escalation design was used for the 
phase I portion (15). Cohorts of 3 patients were enrolled at 
each dose level (Table S1), and an additional 3 patients were 
enrolled if one or more of the first 3 patients developed dose 
limiting toxicity (DLT). Doses of pemetrexed and sirolimus 
were based on cohort assignment. Starting doses of both 
pemetrexed and sirolimus were below FDA-approved doses.
The MTDs were based on the tolerability observed 
during the first 4 weeks of treatment, although several 
patients required dose reduction at later cycles. The MTDs 
were defined as the highest doses at which less than two 
out of six patients experienced DLT. The primary objective 
of phase II component was to determine the activity of 
the combination at the MTD. The objective response rate 
(ORR) was evaluated by study investigators using RECIST 
v1.0 (16).
Prior to the first dose of pemetrexed on cycle 1 day 8 
all patients received a loading dose and one-week lead-in 
course of once daily oral sirolimus. Patients who tolerated 
the lead-in period then continued the same dose of daily 
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sirolimus and received pemetrexed infusion intravenously 
every three weeks at the assigned doses. Each treatment 
cycle consisted of three weeks except cycle 1. Standard 
premedications including corticosteroids, folic acid and 
vitamin B12 were administered to all patients. After several 
patients in the phase II portion with a high steady-state 
sirolimus level developed significant toxicities, the protocol 
was amended. Sirolimus dose reduction was mandated if a 
trough sirolimus level exceeded 15 ng/mL at any subsequent 
cycles.
Dose reduction to the next lower dose level was 
also mandated if patients in either phase I or II portion 
developed DLT during any cycle of the treatment. Patients 
with tumor response of stable disease (SD) or better as 
defined by RECIST1.0 continued the treatment until 
disease progression or intolerable toxicities.
Patient eligibility
Eligible patients  were aged 18 or older,  and had 
histologically confirmed NSCLC that had relapsed after 
at least one standard chemotherapeutic regimen. Patients 
must have had measurable disease for the phase II portion 
of the study. Patients must also have had an expected 
survival time of at least 3 months, an ECOG performance 
status of 0–2, and adequate organ function as determined 
by absolute neutrophil count (ANC) ≥1,500/mL; platelets 
≥100,000/mL; total bilirubin <1.5× upper limit of 
institutional normal (ULN); AST (SGOT) <2.5× ULN; 
ALT (SGPT) <2.5× ULN; serum triglycerides <2.5× ULN; 
serum cholesterol <300 mg/dL; estimated creatinine 
clearance as calculated using the MDRD equation11 must 
be ≥60 mL/min/1.73 m2. Tumor EGFR mutation status was 
not required for study eligibility because genomic analysis 
of the tumor was not routine practice at the time of study 
initiation.
Study assessment
Adverse events (AEs) were evaluated and graded by 
NCI Common Terminology Criteria  for Adverse 
Events (CTCAE Version 3.0) (17), and were monitored 
throughout the study and for up to 28 days after the 
last pemetrexed or sirolimus dose. DLTs were defined 
as any grade 4 hematologic toxicity (except grade 4 
lymphopenia or grade 4 neutropenia with duration of 
7 days or less), febrile neutropenia (neutrophil count 
<1,000 cells/mm3 and temperature ≥38.5 ℃), grade 3 or 4 
hypercholesterolemia (>400 mg/dL or 10.34 mmol/L) or 
grade 3 or 4 hypertriglyceridemia (>5× ULN) in spite of 
treatment with HMG-CoA reductase inhibitors, grade 3 or 
4 diarrhea that has not resolved to grade 2 within 24 hours 
and grade 1 within 48 hours of anti-diarrhea agents, grade 
3 or 4 pneumonitis, grade 3 or 4 mucositis, grade 3 nausea 
or vomiting that did not resolve to grade 2 within 24 hours 
and grade 1 within 48 hours of anti-emetic agents. 
At the dose level identified as the MTD, up to 30 
subjects were required for the phase I portion of the trial 
(5 levels with a maximum of 6 patients per level). If dose 
level 5 was reached and the MTD had not been established, 
dose level 5 would be used as the dose for subjects enrolling 
on the phase II portion of the study. Phase II portion was 
divided into pemetrexed-naïve and pre-treated groups, and 
objective response rates were assessed separately. Patients 
enrolled in the MTD level of phase I portion were added 
onto phase II portion for both safety and efficacy analysis.
Tumor re-staging by CT imaging was conducted at 
screening, after completion of cycle 2, and every six weeks 
thereafter, and radiographic response was evaluated by 
RECIST1.0. Body PET/CT imaging was performed at 
baseline and completion of cycle 2. Patients who developed 
DLTs or completed cycle 1 were considered evaluable for 
AEs. Tumor responses were assessed on an intent-to-treat 
basis. 
On cycle 1 days 7 and 8, blood samples from phase I 
patients were obtained as baseline and selected time points 
after the administration of sirolimus and were analyzed for 
sirolimus and pemetrexed levels. Blood samples for steady-
state sirolimus level were drawn from both phase I and 
II patients at baseline, weekly during cycle 1 and day 1 of 
subsequent cycles. 
Blood samples were collected at baseline, cycle 
1 day 8, cycle 2 day 21 and subsequent every 2 cycles 
for mTOR pathway analysis. Protein extracted from 
PBMC was subsequently analyzed for mTOR pathway 
inhibition (mTOR, P-S6K, 4E-BP1, P-S6, and Akt) by 
immunoblotting (12). Suppression of TS was also evaluated 
by western blotting.
Twenty-two patients were accrued on the phase I portion 
of this trial. Table 1 contains the sirolimus and pemetrexed 
doses for each dose level. Plasma concentrations of cycle 
1 day 8 (C1D8) pemetrexed were measured using a 
validated HPLC-MS/MS method with a calibration range 
of 50–20,000 ng/mL. Sirolimus trough measurements were 
independently analyzed from blood on C1D8. 
A noncompartmental PK analysis of C1D8 pemetrexed 
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was performed on 20 patients using WinNonlin v5 
(Phars ight  Corp,  Mountainview,  CA,  USA) with 
patients receiving either 375 mg/m2 (n=6) or the FDA 
recommended (18) dose of 500 mg/m2 (n=14). The 
maximum plasma concentration (CMAX) was recorded 
as observed values and the area under the plasma-
concentration time curve extrapolated to time infinity 
(AUCINF) was calculated using the Linear Trapezoidal rule. 
Statistics
Following a phase I cohort with up to 6 patients per dose 
level, patients were enrolled in two cohorts depending 
upon whether they were pemetrexed-naïve or had prior 
pemetrexed. Both cohorts employed a Simon two-stage 
phase II optimal design to evaluate the responses, with 
alpha =0.10 and beta =0.10 in each. 
In the pemetrexed-naïve cohort, the objective was to rule 
out a 9% response rate (P0=0.09) in favor of a 34% response 
rate (P1=0.34). The first stage would enroll 7 patients, and 
if there were 0 responses, accrual would end. If 1 or more 
patients responded, accrual would continue until a total of 
20 evaluable patients had been accrued. One to 3 responses 
in 20 patients would have been considered inadequate while 
4 or more of 20 with a response would be desirable. The 
probability of early termination under the null hypothesis 
was 52%.
In the cohort that received prior pemetrexed, the 
objective was to rule out a 5% response rate (P0=0.05) in 
favor of a 20% response rate (P1=0.20). The first stage 
would enroll 12 patients, and if there were 0 responses, 
accrual would end. If 1 or more patients responded, accrual 
would continue until a total of 37 evaluable patients had 
been accrued. One to 3 responses in 37 patients would have 
been considered inadequate while 4 or more of 37 with 
a response would be desirable. The probability of early 
termination under the null hypothesis was 54%.
For PK analysis, the Wilcoxon rank sum test was used 
to test the difference between parameters of interest in two 
groups of patients. The Spearman correlation coefficient (r) 
was used to determine the correlation between continuous 
variables, and was interpreted by the following: strong 
Table 1 Patient characteristics
Clinical characteristics Phase I Phase II Total DL4 (P I/II)
Total No. 22 20 42 27
Median age [range] 57 [33–79] 62 [24–72] 62 [24–79] 61 [24–77]
Male/female 11/11 10/10 21/21 13/14
Histology
Non-Sq 16 17 33 21
Sq 6 3 9 6
PS
0–1 16 11 27 15
2 6 9 15 12
Prior regimens median [range] 2 [1–4] 3 [1–7] 2 [1–7] 2 [1–7]
Prior pemetrexed 0 8 8 8
Pemetrexed naive 22 12 34 19
Prior EGFR-TKI 9 12 21 15
EGFR mutation (positive/tested) 4/13 3/19 7/32 5/25
Kras mutation (positive/tested) 3/14 7/20 10/34 8/26
ALK translocation (positive/tested) 0/3 0/15 0/18 0/18
Non-Sq, non-squamous; Sq, squamous; PS, performance status; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; 
ALK, anaplastic lymphoma kinase; DL, dose level.
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association: |r|>0.7, moderate association: 0.5<|r|<0.7, 
moderate to weak association: 0.3<|r|<0.5, and weak 
association: |r|<0.3. Somers D was used to determine the 
correlation between ordered categorical data and can be 
interpreted similarly to Spearman’s correlation coefficient. 
The Jonckheere-Terpstra trend test was used to test for a 
trend between dose level and C1D8 sirolimus blood trough 
concentration. All P values are two-tailed and unadjusted 
for multiple comparisons. 
Progression-free survival (PFS) was determined from the 
on-study date until the date of death, date of progression, 
or last follow-up; patients who died without progression 
were also considered to be failures for this analysis. The 
probability of PFS as a function of time was determined 
by the Kaplan-Meier method. Fisher’s exact test was used 
to determine the statistical significance of the difference 
between two proportions.
Results
Patient characteristics 
Between November 2008 and June 2012, 42 patients were 
enrolled; 22 in phase I and 20 in the phase II portion. 
Patient characteristics are listed in Table 1. Due to a slow 
accrual rate, the study was prematurely terminated before 
the accrual ceiling was reached. 
Safety
The phase I dose escalation continued up to dose level 5 
(pemetrexed 500 mg/m2, sirolimus 15 mg loading/5 mg 
subsequent), at which one patient developed a DLT (grade 
3 fatigue, Table 2), and two patients required dose reduction 
at cycle 2. Therefore, the decision was made to enroll 
4 more patients in dose level 4 where one patient developed 
a DLT (grade 3 infection). Dose level 4 (pemetrexed 500 
mg/m2, sirolimus 10 mg load/3 mg/day) was determined 
to be the MTD, and all patients enrolled in the phase II 
portion were initially treated at this dose level. However, 
four of the first seven phase II patients developed significant 
AEs. One patient developed grade 5 febrile neutropenia, 
and three patients required dose reduction of sirolimus for 
grade 3 or 4 nonhematologic toxicities (two patients with 
pulmonary toxicities, one with hyponatremia). These four 
patients had a steady-state sirolimus trough level higher 
than 15 ng/mL, whereas only one of the remaining three 
patients who tolerated DL4 had a high sirolimus level. 
Additional dose reduction of sirolimus was thereafter 
mandated in the later part of phase II if patients had a 
sirolimus trough level of 15 ng/mL or higher at any time 
point. 
Of 27 patients enrolled at the MTD/DL4 (7 in phase 
I and 20 in phase II), 13 patients received at least 5 cycles 
of the combination treatment (Table 2: treatment exposure 
and dose reduction), and 20 patients completed at least first 
cycle (Table 2). Twelve patients at all dose levels resulted in 
a dose reduction at subsequent cycles (Table 2) due to AEs 
(n=8) or high sirolimus trough level (n=4). Nevertheless, 
none required further dose modification at DL3. The 
majority (83.3%, 35 of 42) came off study due to disease 
progression.
All AEs related to the study drugs (possible, probable 
and definite) at all dose levels/phases are listed in Table 3. 
The most common hematologic and nonhematologic AEs 
at grade 3–4 were lymphopenia (31%), neutropenia (14%), 
anemia (12%), and leukopenia (10%), hypophosphatemia 
(19%), fatigue (14%), and hyperglycemia (10%). Two 
patients receiving pemetrexed 500 mg/m2 and sirolimus 
3 mg developed grade 5 neutropenia and infection. Both 
patients developed AEs a few days after the first pemetrexed 
infusion and had steady-state sirolimus levels higher than 
15 ng/mL.
Clinical activity 
A total of 27 patients were enrolled at the MTD/
recommended phase II dose (RP2D) and analyzed for 
efficacy (Table 4, Figure 1A). Six (22.2%) patients achieved 
a partial response, 12 (44.4%) had SD and 5 (18.5%) had 
progressive disease. The overall response rate was 22.2%. 
We observed clinical activity in two patients not expected 
to respond to pemetrexed as a single-agent, such as a 
patient who had been treated previously with pemetrexed 
and progressed on it who achieved a PR as well as in a 
patient with squamous histology. Tumor responses were 
more frequent in pemetrexed naïve vs. those with prior 
pemetrexed [5/19 (26.3%) vs. 1/8 (12.5%); P=0.63]. 
This indicates that the pemetrexed-naïve group reached 
at least desirable response as defined in the methods 
section, whereas efficacy in patients with prior exposure to 
pemetrexed group was not adequately evaluated due to an 
underpowered sample size. 
Higher response rates were seen in and non-squamous 
vs. squamous patients [5/21 (23.8%) vs. 1/6 (16.7%); 
P=1.00] and EGFR-mutated patients vs. patients with no 
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EGFR mutations or unknown mutation status [3/5 (60%) 
vs. 3/22 (13.6%); P=0.056]. When another efficacy analysis 
for all patients (n=42) was performed, these trends were 
maintained (Table S2). Survival analysis showed a median 
PFS of 18.4 (95% CI: 7.0–29.4) weeks in patients at the 
MTD (Figure 1B).
PK 
Twenty of the twenty-two enrolled patients on the phase 
I portion of this trial had evaluable data for PK analysis. 
One patient on dose level 1 (taken off study due to brain 
metastasis) and one patient on dose level 4 (taken off study 
due to progressive disease) were not evaluable for PK 
analysis. 
Pemetrexed administered at the 500 mg/m2 dose level 
exhibited a similar exposure and half-life (t1/2) of 144.7 
ug×h/mL and 2.79 h, respectively, as a previous report using 
the same dose, where AUCINF and t1/2 were 158 ug×h/mL 
and 2.62 h, respectively (19). There were no statistically 
significant differences in half-life (P=0.97) or clearance 
(P=0.72) between the two dose levels (Figure S1). However, 
there was a statistical trend of increasing CMAX (P=0.041, 
Figure S2A), but not AUCINF (P=0.31, Figure S2B). 
When comparing C1D8 sirolimus trough blood 
concentrations on each dose level, there is a clear increasing 
trend with dose (Jonckheere-Terpstra trend test P=0.0013) 
(Figure S3). To examine whether increasing sirolimus trough 
levels were associated with pemetrexed PK, sirolimus trough 
levels were plotted against pemetrexed CMAX and AUCINF 
Table 2 Treatment exposure and dose reduction
Variables
Phase I Phase II
Level 1 Level 2 Level 3 Level 4 Level 5 Level 4
No. n=4 n=3 n=3 n=7 n=5 n=20
DLT (phase I) 0 0 0 1 1 NA
No. of completed cycles
0 1 0 0 2 0 5
1 0 0 0 0 0 0
2 2 0 0 1 1 3
3 0 1 0 0 0 1
4 0 1 0 1 1 1
5–6 0 0 2 0 0 3
7–10 0 0 1 0 1 3
11–20 1 1 0 2 2 4
21+ 0 0 0 1 0 0
Reason for discontinuation
Disease progression 4 3 3 5 5 14
Death of unknown cause 0 0 0 0 0 1
Voluntary withdrawal 0 0 0 0 0 2
AEs 0 0 0 1 0 3
Dose reduction in patients ≥1 cycle(s)
Total 0 0 0 1 2 9
Due to AEs 0 0 0 1 2 5
Due to sirolimus trough >15 ng/mL 0 0 0 0 0 4
AEs, adverse events. Dose levels are described in detail in the Table S1. 
253Translational Lung Cancer Research, Vol 8, No 3 June 2019
© Translational lung cancer research. All rights reserved.   Transl Lung Cancer Res 2019;8(3):247-257 | http://dx.doi.org/10.21037/tlcr.2019.04.19
Table 3 Treatment-related adverse events (AEs) at all levels (n=42, phase I/II)
Variables All grades [%] Grade 3–4 [%] Grade 5 [%]
Hematologic
Leukopenia 14 [33] 4 [10]
Neutropenia 16 [38] 6 [14] 1 [2]
Lymphopenia 25 [60] 13 [31]
Anemia 21 [50] 5 [12]
Thrombocytopenia 17 [40] 3 [7]
Nonhematologic
Fatigue 19 [45] 6 [14]
Hypophosphatemia 16 [38] 8 [19]
Nausea/vomiting 16 [38] 1 [2]
Hyperglycemia 15 [36] 4 [10]
Hypomagnesemia 14 [33] 2 [5]
ALT 14 [33] 3 [7]
Hypercholesterolemia 9 [21] 0 [0]
Creatinine 9 [21] 0 [0]
Hypertriglyceridemia 8 [19] 0 [0]
Dyspnea 4 [10] 2 [5]
Infection 6 [14] 2 [5] 1 [2]
ALT, aspartate aminotransferase.
Table 4 Efficacy results at the MTD 
Variables Total
Best overall response [%]† PFS (weeks)
PR SD PD NE median (95% CI)
Intent-to-treat 27 6 [22] 12 5 4 18.4 (7–29.4)
≥1 cycle 20 6 [30] 12 2 0 27.4 (14.1–44)
Non-squamous 21 5 [24] 9 4 3 19.4 (6.9–41)
Squamous 6 1 [17] 3 1 1 15.5 (5.9–55)
Prior pemetrexed 8 1 [13] 5 1 1 19.6 (2.9–43)
Pemetrexed naïve 19 5 [26] 7 4 3 16.9 (6.9–29.4)
Prior EGFR-TKI 15 5 [33] 7 3 0 19.7 (9.1–44)
EGFR WT/NA 22 3 [14] 12 3 4 17.8 (5.9–28)
EGFR mutant 5 3 [60] 0 2 0 43 (9.1–undefined)
Kras WT/NA 19 6 [32] 8 4 2 19.4 (9.1–43)
Kras mutant 8 0 [0] 4 1 2 12 [2–41]
†, response percentages are displayed based on all patients, not restricted to those evaluable for response. EGFR, epidermal growth 
factor receptor; TKI, tyrosine kinase inhibitor; WT, wild-type; NA, not analyzed; PR, partial response; SD, stable disease; PD, progressive 
disease; NE, not evaluable; PFS, progression-free survival.
254 Komiya et al. Pemetrexed plus sirolimus in NSCLC
© Translational lung cancer research. All rights reserved.   Transl Lung Cancer Res 2019;8(3):247-257 | http://dx.doi.org/10.21037/tlcr.2019.04.19
(Figure S4). There were only moderate or weak correlations 
between sirolimus trough levels and pemetrexed CMAX or 
AUCINF. This suggests that increasing sirolimus levels are 
not associated with pemetrexed PK. 
Pharmacodynamics
Assessment for mTOR in PBMC was performed in a 
total of 23 available patients. No inhibition on mTOR 
signaling was observed at DL 1 or 2 (Figure S5A). P-S6K 
and P-S6 were inhibited in response to sirolimus treatment 
in patients treated at the MTD (Figures 2 and S5B,C). 
Feedback activation of P-Akt, which is generally considered 
as a resistance mechanism to mTOR-targeted therapies 
such as rapamycin that only target mTORC1 complexes 
was not observed in the majority of patients. To determine 
if concurrent administration of sirolimus can influence 
pemetrexed-induced activation of TS at the MTD, western 
blotting with protein derived from PBMC was performed 
in a total of 18 patients who were treated at the MTD. 
In contrast to our in vitro and in vivo mouse study, where 
sirolimus blocked activation of TS in cells/tumor tissue (14), 
TS activation was only temporarily affected by concurrent 
treatment of sirolimus (Figure 2). 
Discussion
In this phase I/II study we demonstrate the tolerability 
and clinical activity of a combination of pemetrexed with 
sirolimus in patients with recurrent NSCLC. Pemetrexed 
is approved for first line therapy of non-squamous NSCLC 
as part of a platinum doublet and is frequently used for 
treatment of recurrent non-squamous NSCLC. However, 
response rates remain low and the survival benefit is modest. 
Various attempts to combine pemetrexed with other 
cytotoxic drugs have not shown any benefit over pemetrexed 
alone (20-23). This group and others have shown that 
the Akt-mTOR signaling cascade is frequently activated 
in NSCLC cells, indicating that TORC1 inhibitors such 
as sirolimus could be potential therapies for NSCLC 
(7,8). Previously published in vitro and in vivo studies also 
showed enhanced anti-cancer efficacy of the combination 
of pemetrexed and sirolimus over either agent alone in 
NSCLC (12). Based on these preclinical observations, the 
current study was designed to evaluate the combination of 
pemetrexed and sirolimus in recurrent NSCLC.
The best overall response for intent-to-treat patients at 
pemetrexed 500 mg/m2/sirolimus 10 mg load/3 mg/day was 
22% which appears to be higher than historical data from 
single-agent pemetrexed studies in unselected patients in 
the literature (4). Other regimens using pemetrexed with 
mTOR inhibitors yielded relatively low response rates of 
0–11% (13,14). The response rate was higher in patients 
with EGFR mutation. Other prior studies also reported 
higher response rate to single-agent pemetrexed in EGFR-
mutated or ALK-rearranged NSCLC (24-27). The reason 
for better response in theses populations is unclear.
What mechanisms might underlie the combination of 
pemetrexed and sirolimus? Preclinical and clinical studies 
indicated that squamous carcinoma has high TS expression 
which is one of molecular targets of the anti-folate agent 
pemetrexed (26). However, it has also been shown that a 
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Figure 1 Of the 27 patients at the MTD, seven developed progression (n=3), toxicities (n=3), or patient withdrawal (n=1) prior to 
completion of cycle 1. Two patients clinically progressed before completion of initial re-staging. (A) RECIST % for best response in 
evaluable patients who completed re-staging after 2 cycles (n=18). The dotted line indicates 30% reduction from the baseline. *, RECIST =0%; 
blue bars, adenocarcinoma; red bars, squamous cell carcinoma; shaded bars, prior pemetrexed exposure +. (B) Progression-free survival (PFS) 
in evaluable patients at the MTD (n=27). MTD, maximum tolerated dose.
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low level of TS expression is associated with high anti-
tumor activity of pemetrexed (26-29). This suggests that the 
clinical responsiveness to pemetrexed in squamous NSCLC 
might be improved if additional agents were able to 
decrease TS expression. Our group has been investigating 
potential mechanism of action for synergistic effect of 
pemetrexed and sirolimus in preclinical models. Preclinical 
studies suggest that sirolimus blocks pemetrexed-induced 
TS activation in tumor tissue (12), which in turn is expected 
to enhance sensitivity to pemetrexed according to the 
multiple preclinical studies (27-29). This clinical trial 
intended to test this hypothesis by correlative studies. It 
was not feasible to analyze tumor tissue for TS activation; 
however, contrary to the preclinical in vitro and in vivo 
study, analysis in PBMC showed that an inhibitory effect of 
sirolimus on TS activation was observed but only temporary 
(Figure 2). Sustained suppression of TS level in tumor tissue 
might be required to further enhance anti-tumor effect 
of pemetrexed. Although these observations still need to 
be validated, inhibition of TS activation is a mechanism 
that may support the observation of activity with the 
combination in this phase I/II study.
The combination of pemetrexed and sirolimus in 
this study was relatively well tolerated, and appeared to 
have no new safety concern when compared with other 
combinations of pemetrexed with an mTOR inhibitor 
except as described below (13,14). Although grade 3 and 
higher neutropenia frequently occurred in other studies 
using pemetrexed and mTOR inhibitors (37–60%) (13,14), 
it was observed in 14% of participants in this study. Other 
hematological and nonhematological grade 3–4 events such 
as dyspnea (5%) were also less frequently or similarly seen 
in this study. As described earlier, early deaths possibly 
attributable to the study drugs occurred in two patients 
(4.8%), whereas six deaths on study were reported in 
another study using pemetrexed and everolimus in 43 
NSCLC patients (13). The two treatment-related deaths in 
the first 7 patients in phase II led to the modification of the 
design to incorporate monitoring of trough sirolimus level. 
Subsequent 20 patients did tolerate well without grade 
5 toxicities. Careful monitoring of myelosuppression is 
strongly recommended for future studies. 
Conclusions
The findings from this study indicate that the combination 
of pemetrexed and sirolimus is feasible and active in patients 
with heavily pretreated, advanced NSCLC. Additional 
clinical trials would be required to optimize dosing 
schedules to minimize toxicity and maximize benefit and 
identify the role of this combination in the context of the 
evolving therapeutic landscape of NSCLC.
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Supplementary
Table S1 Dose levels
Dose level Pemetrexed (iv), mg/m2 Sirolimus (po), mg load/mg/day
−1 186 1.5/0.5
1 375 3/1
2 375 6/2
3 500 6/2
4 500 10/3
5 500 15/5
Table S2 Efficacy in all dose levels
Variables Total
Best overall response [%]† PFS (weeks)‡
PR SD PD NE Median (95% CI)
Intent-to-treat 42 9 [21] 19 7 7 18.4 (10–28.9)
Non-squamous 33 8 [24] 16 4 5 19.6 (13.7–41)
Squamous 9 1 [11] 3 3 2 8 (1.4–26.9)
Prior pemetrexed 8 1 [13] 5 1 1 19.5 (2.9–43)
Pemetrexed naïve 34 8 [24] 14 6 6 18.3 (9.1–28.9)
Prior EGFR TKI 21 7 [33] 10 3 1 19 (13.7–43)
EGFR WT/NA 35 6 [17] 17 5 7 18.3 (8.9–26.9)
EGFR mutant 7 3 [43] 2 2 0 43.5 (9.1–undefined)
Kras WT/NA 32 9 [28] 13 6 5 19 (10–29.4)
Kras mutant 10 0 [0] 6 1 2 17.6 [2–41]
†, response percentages are displayed based on all treated patients, not restricted to those evaluable for response; ‡, PFS based on up to 
41 patients with follow-up data. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; WT, wild-type; NA, not analyzed; 
PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; PFS, progression free survival.
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Figure S1 Difference in half-life (A) and clearance (B) between pemetrexed doses. There is a clear increasing trend with dose (Jonckheere-
Terpstra trend test P=0.0013) when comparing C1D8 sirolimus trough blood concentrations on each dose level.
Figure S2 Difference in CMAX (A) and AUCINF (B) between pemetrexed doses.
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Figure S3 Increased C1D8 sirolimus trough levels with dose.
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Figure S4 Lack of correlation between sirolimus trough levels and CMAX (A) or AUCINF (B).
Dose level 1
Pemetrexed: 375 mg/m2
Sirolimus: 1 mg daily
Dose level 2
Pemetrexed: 375 mg/m2 
Sirolimus: 2 mg daily
      01–08               03–09            04–09   05–09              06–09               07–09
A         B        C   A       B     C   A       B       C A        B         C   A        B      C   A       B       C
p-S6K 
(T389)
* * *
p-S6 
(S235/6)
4E-BP1
p-Akt 
(S473)
B-actin
TS
p-S6 
(S235/6)
p-Akt 
(S473)
B-actin
TS
34–11           39–12         40–12         41–12
*A     B     C  A    B     C  A     B     C   A    B   C
p-S6 
(S235/6)
p-Akt 
(S473)
B-actin
TS
Dose level 4 (MTD)
Pemetrexed: 500 mg/m2
Sirolimus: 3 mg daily
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Figure S5 Biomarker analyses for additional patient samples at DL 1, 2, 4 and 5. (A) baseline; (B) cycle 1 day 8; (C) cycle 3 day 21. *, positive 
control (H460 cells treated with pemetrexed). Modulation of mTOR pathway was not observed at DL 1 and 2.
